The Application of Current Proposed Venous Thromboembolism Risk Assessment Model for Ambulatory Patients With Cancer.
Venous thromboembolism (VTE) is a commonly encountered problem in patients with cancer. In recent years, cancer treatment paradigm has shifted with most therapy offered in ambulatory outpatient settings. Excess of half VTEs in patients with cancer occur in outpatient settings without prior hospitalization, where current practice guidelines do not recommend routine prophylaxis. Risk assessment models (RAMs) for VTE in such patients were recently introduced. This study aims to assess the practical application of one of these models in clinical practice. Medical records and hospital electronic database were searched for patients with cancer having VTE. Known risk factors were collected, and risk assessment was done using the Khorana RAM. Over a 10-year period, 346 patients developed VTE in ambulatory settings. Median age was 57 and 59.0% were females. Lower extremities were involved in 196 (56.6%), while 96 (27.7%) had pulmonary embolism. Most (76.6%) patients had stage IV disease, only 9.0% had stage I or II disease. Only 156 (45.1%) patients were on active chemotherapy, for whom Khorana risk assessment score was calculated. In these patients, high risk was identified in 31 (19.9%) patients, while 81 (51.9%) had intermediate risk and 44 (28.2%) had low risk. No patients were on prophylaxis prior to VTE. Most ambulatory patients with cancer who developed VTE were not on chemotherapy, and many of those who were on active treatment had low Khorana risk scores. This illustrates the need to modify the model or develop a new one that takes into consideration this group of patients.
1 Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Hikmat
H
Abdel-Razeq
2 Department of Radiology, King Hussein Cancer Center, Amman, Jordan.
Asem
A
Mansour
1 Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Salwa S
SS
Saadeh
1 Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Mahmoud
M
Abu-Nasser
1 Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Mohammad
M
Makoseh
1 Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Murad
M
Salam
1 Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Alaa
A
Abufara
3 Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan.
Yousef
Y
Ismael
2 Department of Radiology, King Hussein Cancer Center, Amman, Jordan.
Alaa
A
Ibrahim
1 Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Ghaleb
G
Khirfan
1 Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Mohammad
M
Ibrahim
D000553:Ambulatory Care; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D010045:Outpatients; D018570:Risk Assessment; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000209:etiology*
cancer; deep venous thrombosis; thrombosis prophylaxis; venous thromboembolism